Last week Oleg Kurilov, General Director of GCT in Kazakhstan took part at the Virtual Pharmaceutical Marathon. The event was dedicated to the pharmaceutical market in Kazakhstan. It focused on the industry strategies during the COVID-19 Pandemic. The topics included interaction with the Regulatory Authority, pharmacy and patients as well as price regulation and development of digital promotion channels.
In January 2020, GCT expanded its operations to Kazakhstan. The country is located in Central Asia and is part of The Eurasian Economic Union (EAEU). Kazakhstan is now actively preparing to transition to registering drugs according to the EAEU rules in 2021. It is an attractive for clinical research and a rapidly developing region. Conducting clinical trials in Kazakhstan is cost effective and offers high standards of quality with adherence to ICH GCP.